絞り込み

16514

広告

「ibritumomab tiuxetan」の検索結果

567件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

Management of newly diagnosed high-risk and intermediate-risk follicular lymphoma with Y ibritumomab tiuxetan in a phase II study.

Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience.

Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium-Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-Cell Lymphoma.

A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.

Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin Lymphoma: Final Results of a Phase II Study.

Ibritumomab tiuxetan (Zevalin) and elevated serum human anti-murine antibody (HAMA).

Complex upper arm reconstruction using an antero-lateral thigh free flap after an extravasation of Yttrium-90-ibritumomab Tiuxetan: A case report and literature review.

Treatment for mantle cell lymphoma.

A phase 1 trial of (90)Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma.

Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma.

Whither Radioimmunotherapy: To Be or Not To Be?

Phase 2 study of CHOP-R-14 followed by (90)Y-ibritumomab tiuxetan in patients with previously untreated diffuse large B-cell lymphoma.

Possible novel agents in marginal zone lymphoma.

Cloning and molecular characterization of the cDNAs encoding the variable regions of an anti-CD20 monoclonal antibody.

Phase II Study of Yttrium-90 Ibritumomab Tiuxetan Plus High Dose BEAM for Non-Hodgkin Lymphoma: the Role of Histology.

Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.

Discriminatory power of the 111-indium scan (111-In) in the prediction of altered biodistribution of radio-immunoconjugate in the 90-yttrium ibritumomab tiuxetan therapeutic regimen: Meta-analysis of five clinical trials and 9 years of post-approval safety data.

Addition of low-dose, involved-field external beam radiotherapy just prior to radioimmunotherapy for CD20+ lymphoma: "Priming" cell death pathways?

Phase II study of short-course CHOP-rituximab followed by (90)y ibritumomab tiuxetan as first-line treatment for follicular lymphoma: Analysis of FcγR variants.

Y(90) ibritumomab tiuxetan with maintenance rituximab as initial therapy for high tumor burden follicular lymphoma: A Wisconsin Oncology Network study.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
Sort by
※並べ替えは表示に時間がかかります